Bifunctional crosslinking ligands for transthyretin

Area of Science:

• Biochemistry
• Pharmacology
• Genetics

Background:

• Transthyretin (TTR) amyloidosis is a severe disease caused by amyloid fibril deposition.
• Reducing precursor protein levels can halt amyloidosis progression.
• Previous success in depleting serum amyloid P component (SAP) suggested a similar approach for TTR.

Purpose of the Study:

• To investigate if TTR could be therapeutically depleted by crosslinking its molecules.
• To develop specific bivalent ligands to crosslink TTR and promote its clearance.

Main Methods:

• Preparation of bivalent ligands targeting TTR's thyroxine binding sites.
• Formation of stable TTR-ligand complexes in vitro and in vivo.
• Assessment of clearance rates of TTR-ligand complexes in mouse models.

Main Results:

• Chemically crosslinked human TTR showed rapid clearance in mice.
• Bivalent ligands formed stable TTR-ligand complexes.
• These complexes did not exhibit accelerated clearance compared to native TTR in vivo.

Conclusions:

• Therapeutic strategies targeting TTR amyloidosis require further development.
• Accelerated clearance of TTR is necessary for effective depletion.
• Additional mechanisms beyond simple crosslinking are needed for therapeutic TTR depletion.